BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab profit margin
Profit margin (net margin) is net income as a percentage of revenue.
BioNexus Gene Lab's profit margin for the twelve months ending Jun 30, 2026 was -82.4%. For fiscal 2025 it was -40.2%, against -16.8% the year before. The highest annual figure on record is 12.5% in fiscal 2018.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -40.2% | −23.4 |
| FY2024 | Dec 31, 2024 | -16.8% | +10.1 |
| FY2023 | Dec 31, 2023 | -26.9% | −23.6 |
| FY2022 | Dec 31, 2022 | -3.3% | −8.9 |
| FY2021 | Dec 31, 2021 | 5.6% | −4.0 |
| FY2020 | Dec 31, 2020 | 9.6% | +203.7 |
| FY2019 | Dec 31, 2019 | -194.1% | −206.6 |
| FY2018 | Dec 31, 2018 | 12.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -376.1% | −348.9 |
| Q1 FY2026 | Mar 31, 2026 | -2379.7% | −2350.5 |
| Q4 FY2025 | Dec 31, 2025 | -214.2% | −200.4 |
| Q3 FY2025 | Sep 30, 2025 | -27.9% | +23.3 |
| Q2 FY2025 | Jun 30, 2025 | -27.3% | −37.3 |
| Q1 FY2025 | Mar 31, 2025 | -29.2% | −24.8 |
| Q4 FY2024 | Dec 31, 2024 | -13.8% | −27.4 |
| Q3 FY2024 | Sep 30, 2024 | -51.1% | +51.0 |
| Q2 FY2024 | Jun 30, 2024 | 10.1% | +20.2 |
| Q1 FY2024 | Mar 31, 2024 | -4.4% | −1.5 |
| Q4 FY2023 | Dec 31, 2023 | 13.6% | +19.1 |
| Q3 FY2023 | Sep 30, 2023 | -102.2% | −99.2 |
| Q2 FY2023 | Jun 30, 2023 | -10.1% | −4.5 |
| Q1 FY2023 | Mar 31, 2023 | -2.9% | −3.5 |
| Q4 FY2022 | Dec 31, 2022 | -5.5% | −8.3 |
| Q3 FY2022 | Sep 30, 2022 | -3.0% | −11.3 |
| Q2 FY2022 | Jun 30, 2022 | -5.6% | −6.5 |
| Q1 FY2022 | Mar 31, 2022 | 0.6% | −9.3 |
| Q4 FY2021 | Dec 31, 2021 | 2.7% | +7.0 |
| Q3 FY2021 | Sep 30, 2021 | 8.3% | +0.7 |
| Q2 FY2021 | Jun 30, 2021 | 0.9% | +4.2 |
| Q1 FY2021 | Mar 31, 2021 | 9.8% | −25.0 |
| Q4 FY2020 | Dec 31, 2020 | -4.2% | +170.3 |
| Q3 FY2020 | Sep 30, 2020 | 7.6% | +98.7 |
| Q2 FY2020 | Jun 30, 2020 | -3.2% | +322.0 |
| Q1 FY2020 | Mar 31, 2020 | 34.8% | +253.7 |
| Q4 FY2019 | Dec 31, 2019 | -174.5% | +494.9 |
| Q3 FY2019 | Sep 30, 2019 | -91.1% | +6.0 |
| Q2 FY2019 | Jun 30, 2019 | -325.2% | −289.8 |
| Q1 FY2019 | Mar 31, 2019 | -218.8% | – |
| Q4 FY2018 | Dec 31, 2018 | -669.4% | – |
| Q3 FY2018 | Sep 30, 2018 | -97.1% | – |
| Q2 FY2018 | Jun 30, 2018 | -35.5% | – |
See a number that looks wrong?